Pharmaceutical Executive, Mar 1, 2010 - Pharmaceutical Executive

ADVERTISEMENT
Pharmaceutical Executive, Mar 1, 2010
Features
The New Merck's Move on Emerging Markets
By William Looney
Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?
Ad Stars 2010
By George Koroneos
The faces and names behind the year's best pharmaceutical advertising.
Sixth Annual Press Audit
By George P. Sillup , Stephen J. Porth
Pricing, promotion, and the unfinished story of healthcare reform dominated the news last year.
The Race Is On
By Walter Armstrong
Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?
Columns
Moving Beyond Compliant Social Media
By Kevin H. Nalty
Pharma companies need a clear online policy that addresses employee obligations, monitoring guidelines, and engagement roles.
Washington Report
E-Health to Drive Drug Safety
By Jill Wechsler
FDA's new Sentinel System is going live, but the signals may be difficult to assess.
Regulatory
Managing REMS for the Long Term
By Ansis Helmanis
Obligations to fund and support costly studies can extend beyond the period of market exclusivity, giving generics competitors an advantage.
Back Page
Laughter is the Best Medicine
By Oriana Schwindt
Here are five pharmaceutical advertisement parodies that will make you howl 'till it hurts.
Strategy
Stay Ahead of the Technology Curve
In a digital world, vast quantities of data at hand are a powerful asset. Managing that information is key to seizing competitive advantage.
From the Editor
All Things to All People?
By William Looney
Is it possible to remain commercially relevant just as a developer and distributor of drugs? Are there equivalent profits in a larger set of commitments?

ADVERTISEMENT

Click here